Eric Meier

Eric Meier has diverse work experience in various industries. Eric started their career as a Program Manager at Protocol Systems, Inc., a patient monitoring and defibrillator company, where they worked from 1992 to 1996. Eric then joined Johnson & Johnson as an Executive Director from 1996 to 2000.

In 2000, Meier became President & CEO of Calypso Medical, a company specializing in real-time tumor motion tracking during radiation therapy. Eric led Calypso Medical until 2010 when the company was acquired by Varian Medical Systems.

After Calypso Medical, Meier became President & CEO of Cervel Neurotech, Inc. from 2010 to 2015, leading the development of a novel non-invasive neuromodulation platform for the treatment of depression, pain, and addiction. Rio Grande Neurosciences acquired Cervel Neurotech in 2015.

From 2004 to 2015, Meier also served as a Board Member for the Medical Device Manufacturers Association (MDMA).

Meier's next role was as a Board Member at Ziba Design from 2000 to 2016. Eric also served as a Board Member for the Doernbecher Foundation from 2013 to 2017.

In 2017, Meier took on two roles: Board Member at the Deep Blues Festival and Advisor at the Oregon Health & Science University-Portland State University School of Public Health.

Meier's most recent position is as President & CEO of Owl, a leading provider of precision care management solutions for behavioral health. Eric has been with the company since 2015, where they integrate measurement-based care, clinical decision support, and data insights into existing treatment workflows through its cloud-based platform.

Eric Meier attended Duke University, where they obtained a Bachelor of Science in Biomedical Engineering. Eric also attended Menlo School, although no degree or field of study information is provided for this institution. Lastly, Eric Meier pursued an MBA at the Stanford University Graduate School of Business.